PATH
Menu

This article, published in Human Vaccines (Human Vaccines 5:8, 1-7; August 2009), details a collaborative effort between PATH, Arecor, and the University of Colorado Denver School of Pharmacy that has resulted in a new formulation for recombinant hepatitis B vaccine that demonstrates improved stability at elevated temperatures. The formulation exhibited 9-week stability at 55°C and was also shown to be stable at both 37°C and 45°C for at least six months. This new vaccine formulation has the potential to be stored at room temperature for part of its shelf life and will help ensure the potency of the vaccine in areas where the cold chain is insufficient.

Author(s): Jezek J, Chen D, Watson L, et al.

Corporate author(s): PATH, Arecor, University of Colorado

Publication date: August 2009

Available materials

English

Some digital files may be saved at low resolutions to conserve file size. Versions with higher quality may be available; see the contact information below to enquire.

Related regions: Global

See also:

For more information…

Contact: PATH Publications
Email: publications@path.org
Mailing address: PATH, PO Box 900922, Seattle, WA 98109 USA